{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:59:31Z","timestamp":1788587971970,"version":"build-2803163510"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Reirradiation has emerged as a potentially valuable treatment strategy for recurrent glioblastoma, a disease characterized by inevitable local progression despite aggressive multimodal first-line therapy. Recent advances in radiotherapy techniques, improved patient selection, and evolving systemic treatment combinations have renewed clinical interest in this approach. This is reflected by recent publication of the first international consensus guidelines (ESTRO\/EANO) and the initiation of an European phase III randomized trial on reirradiation of patients with recurrent glioblastoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Retrospective and early-phase prospective studies have demonstrated that reirradiation is feasible and well tolerated in selected patients, with median overall survival ranging from 7 to 13\u200amonths. The ESTRO\/EANO guidelines on reirradiation of glioma provide standardized recommendations for patient selection, dose constraints, and target volume delineation. Meta-analyses suggest improved outcomes when reirradiation is combined with systemic therapies, such as bevacizumab or lomustine. The phase III EORTC-2227-BTG (LEGATO) trial will provide definitive data on survival benefit.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Reirradiation is gaining acceptance as a palliative yet potentially impactful treatment for recurrent glioblastoma. While current evidence supports its use in selected cases, results from ongoing phase III LEGATO trial will determine its future role in standard care and inform evidence-based clinical decision-making.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cco.0000000000001192","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:19Z","timestamp":1759881619000},"page":"580-588","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Reirradiation in recurrent glioblastoma"],"prefix":"10.1097","volume":"37","author":[{"given":"Tomas","family":"Kazda","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Masaryk Memorial Cancer Institute"},{"name":"Department of Radiation Oncology, Faculty of Medicine, Masaryk University"},{"name":"Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Hnidakova","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Masaryk Memorial Cancer Institute"},{"name":"Department of Radiation Oncology, Faculty of Medicine, Masaryk University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Minniti","sequence":"additional","affiliation":[{"name":"Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome and Policlinico Umberto I, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"R1-20251010","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"R2-20251010","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/s41591-025-03512-1","article-title":"Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma","volume":"31","author":"Long","year":"2025","journal-title":"Nat Med"},{"key":"R3-20251010","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"R4-20251010","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/WCO.0000000000001320","article-title":"Updates for newly diagnosed and recurrent glioblastoma: a review of recent clinical trials","volume":"37","author":"Fukushima","year":"2024","journal-title":"Curr Opin Neurol"},{"key":"R5-20251010","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s11060-023-04441-0","article-title":"Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity","volume":"164","author":"Marwah","year":"2023","journal-title":"J Neurooncol"},{"key":"R6-20251010","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/archneurol.2011.2910","article-title":"Addressing diffuse glioma as a systemic brain disease with single-cell analysis","volume":"69","author":"Sahm","year":"2012","journal-title":"Arch Neurol"},{"key":"R7-20251010","doi-asserted-by":"crossref","first-page":"109435","DOI":"10.1016\/j.radonc.2022.11.024","article-title":"Feasibility of clinical target volume reduction for glioblastoma treated with standard chemoradiation based on patterns of failure analysis","volume":"181","author":"Minniti","year":"2023","journal-title":"Radiother Oncol"},{"key":"R8-20251010","doi-asserted-by":"crossref","first-page":"104261","DOI":"10.1016\/j.critrevonc.2024.104261","article-title":"Decoding the puzzle: a multidisciplinary systematic review of adult brainstem glioma","volume":"196","author":"Ius","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"R9-20251010","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/1748-717X-8-287","article-title":"Analysis of equivalent uniform dose (EUD) and conventional radiation treatment parameters after primary and re-irradiation of malignant glioma","volume":"8","author":"Niyazi","year":"2013","journal-title":"Radiat Oncol"},{"key":"R10-20251010","first-page":"e68820","article-title":"The patterns of failure and prognostic impact of tumor location in patients undergoing reirradiation for glioblastoma","volume":"16","author":"Reinders","year":"2024","journal-title":"Cureus"},{"key":"R11-20251010","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/S1470-2045(22)00447-8","article-title":"European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making [published correction appears in Lancet Oncol. 2022; 23:e492]","volume":"23","author":"Andratschke","year":"2022","journal-title":"Lancet Oncol"},{"key":"R12-20251010","doi-asserted-by":"crossref","first-page":"109768","DOI":"10.1016\/j.radonc.2023.109768","article-title":"Dosimetric patterns of failure in the era of novel chemoradiotherapy in newly-diagnosed glioblastoma patients","volume":"188","author":"Seaberg","year":"2023","journal-title":"Radiother Oncol"},{"key":"R13-20251010","doi-asserted-by":"crossref","first-page":"110696","DOI":"10.1016\/j.radonc.2024.110696","article-title":"ESTRO\/EANO recommendation on reirradiation of glioblastoma","volume":"204","author":"Andratschke","year":"2025","journal-title":"Radiother Oncol"},{"key":"R14-20251010","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/s13063-024-08213-7","article-title":"Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study","volume":"25","author":"Preusser","year":"2024","journal-title":"Trials"},{"key":"R15-20251010","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/0360-3016(79)90553-4","article-title":"An analysis of dose-effect relationship in the radiotherapy of malignant gliomas","volume":"5","author":"Walker","year":"1979","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R16-20251010","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.hoc.2024.11.008","article-title":"FLASH radiotherapy: from in vivo data to clinical translation","volume":"39","author":"Manring","year":"2025","journal-title":"Hematol Oncol Clin North Am"},{"key":"R17-20251010","doi-asserted-by":"crossref","first-page":"102616","DOI":"10.1016\/j.ejmp.2023.102616","article-title":"Clinical aspects of spatially fractionated radiation therapy treatments","volume":"111","author":"Grams","year":"2023","journal-title":"Phys Med"},{"key":"R18-20251010","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s12672-025-02487-2","article-title":"Progress of the application of spatially fractionated radiation therapy in palliative treatment of tumors","volume":"16","author":"Zhao","year":"2025","journal-title":"Discov Oncol"},{"key":"R19-20251010","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s43856-025-00809-7","article-title":"Mini-GRID therapy delivers optimised spatially fractionated radiation therapy using a flattening free filter accelerator","volume":"5","author":"Acu\u00f1a","year":"2025","journal-title":"Commun Med (Lond)"},{"key":"R20-20251010","first-page":"100585","article-title":"Study protocol: PreOperative Brain Irradiation in Glioblastoma (POBIG) - a phase I trial","volume":"39","author":"Waqar","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"R21-20251010","doi-asserted-by":"crossref","first-page":"101732","DOI":"10.1016\/j.adro.2025.101732","article-title":"Boswellia serrata for the management of radiation-induced cerebral edema and necrosis: a systematic meta-narrative review of clinical evidence","volume":"10","author":"Dejonckheere","year":"2025","journal-title":"Adv Radiat Oncol"},{"key":"R22-20251010","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3390\/tomography10090110","article-title":"Radiomic analysis of treatment effect for patients with radiation necrosis treated with pentoxifylline and vitamin E","volume":"10","author":"Patel","year":"2024","journal-title":"Tomography"},{"key":"R23-20251010","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11060-024-04709-z","article-title":"The impact of cancer patient pathway on timing of radiotherapy and survival: a cohort study in glioblastoma patients","volume":"169","author":"Blakstad","year":"2024","journal-title":"J Neurooncol"},{"key":"R24-20251010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.healthpol.2011.11.001","article-title":"Cancer patient pathways in Denmark as a joint effort between bureaucrats, health professionals and politicians--a national Danish project","volume":"105","author":"Probst","year":"2012","journal-title":"Health Policy"},{"key":"R25-20251010","doi-asserted-by":"crossref","first-page":"109663","DOI":"10.1016\/j.radonc.2023.109663","article-title":"ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma","volume":"184","author":"Niyazi","year":"2023","journal-title":"Radiother Oncol"},{"key":"R26-20251010","doi-asserted-by":"crossref","first-page":"110594","DOI":"10.1016\/j.radonc.2024.110594","article-title":"ESTRO-EANO guideline on target delineation and radiotherapy for IDH-mutant WHO CNS grade 2 and 3 diffuse glioma","volume":"202","author":"Baumert","year":"2025","journal-title":"Radiother Oncol"},{"key":"R27-20251010","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.22.00164","article-title":"NRG Oncology\/RTOG1205: a randomized phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma","volume":"41","author":"Tsien","year":"2023","journal-title":"J Clin Oncol"},{"key":"R28-20251010","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"R29-20251010","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","article-title":"Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial","volume":"15","author":"Taal","year":"2014","journal-title":"Lancet Oncol"},{"key":"R30-20251010","first-page":"100706","article-title":"Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO","volume":"45","author":"Bodensohn","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"R31-20251010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13014-021-01767-9","article-title":"Current status and recent advances in reirradiation of glioblastoma","volume":"16","author":"Minniti","year":"2021","journal-title":"Radiat Oncol"},{"key":"R32-20251010","first-page":"369","article-title":"Controversies in neuro-oncology: Focal proton versus photon radiation therapy for adult brain tumors","volume":"11","author":"Eekers","year":"2024","journal-title":"Neurooncol Pract"},{"key":"R33-20251010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11060-024-04607-4","article-title":"Hypofractionated stereotactic re-irradiation for progressive glioblastoma: twelve years\u2019 experience of a single center","volume":"167","author":"Yilmaz","year":"2024","journal-title":"J Neurooncol"},{"key":"R34-20251010","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.mayocp.2023.04.013","article-title":"Clinical trials overview: from explanatory to pragmatic clinical trials","volume":"98","author":"Le-Rademacher","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"R35-20251010","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3390\/jpm14050538","article-title":"Preferred imaging for target volume delineation for radiotherapy of recurrent glioblastoma: a literature review of the available evidence","volume":"14","author":"Cuccia","year":"2024","journal-title":"J Pers Med"},{"key":"R36-20251010","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.4103\/ATMR.ATMR_128_24","article-title":"Reirradiation with or without bevacizumab for recurrent or progressive high-grade gliomas: a systematic review and meta-analysis","volume":"1","author":"Aleid","year":"2025","journal-title":"J Adv Trends Med Res"},{"key":"R37-20251010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/neuonc\/noae209","article-title":"Point\/Counterpoint: The role of reirradiation in recurrent glioblastoma","volume":"27","author":"Rahman","year":"2025","journal-title":"Neuro Oncol"},{"key":"R38-20251010","doi-asserted-by":"crossref","first-page":"110624","DOI":"10.1016\/j.radonc.2024.110624","article-title":"Ongoing prospective studies on reirradiation: a systematic review of a clinical trials database","volume":"202","author":"Willmann","year":"2025","journal-title":"Radiother Oncol"},{"key":"R39-20251010","doi-asserted-by":"crossref","first-page":"103800","DOI":"10.1016\/j.clon.2025.103800","article-title":"Carbon ion radiotherapy reirradiation for recurrent malignancy: a systematic assessment","volume":"42","author":"Ruan","year":"2025","journal-title":"Clin Oncol (R Coll Radiol)"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000001192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:00:26Z","timestamp":1760101226000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000001192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000001192","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]}}}